Cory Renauer
Value, research analyst, biotech, small-cap

Aegerion's Lomitapide Launch Progressing Better Than Expected

In June 2013, I gave Aegerion Pharmaceuticals (NASDAQ:AEGR) an enthusiastic write up based largely on two overlooked facts. Outdated estimates put the rate of homozygous familial [HoFH] at about one in a million. At $295,000 per patient, per year, there was reasonable concern about the adoption of Juxtapid by an extremely limited potential patient base. The first source of opportunity I highlighted, back in June, stemmed from the financial community's lack of understanding of the founder effect in isolated populations. In short, the global rate of HoFH is much higher than just one in a million. I also noted that lomitapide's impending EC marketing approval, coupled with a firm denial of mipomersen, make it the only effective treatment...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details